Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal [Yahoo! Finance]
Tourmaline Bio, Inc. (TRML)
Company Research
Source: Yahoo! Finance
Novartis ( NOVN Financials ) said Tuesday it will acquire Tourmaline Bio in a $1.4 billion deal as it looks to strengthen its cardiovascular disease portfolio. Is XSWX:NOVN fairly valued? Test your thesis with our free DCF calculator. The Swiss drugmaker will pay $48 per share for the New York-based biopharmaceutical company, which is developing pacibekitug, a targeted therapy aimed at reducing systemic inflammation in patients with atherosclerotic cardiovascular disease. The treatment candidate is Phase III-ready. The boards of both companies have approved the transaction. Novartis will launch a tender offer to purchase all outstanding shares of Tourmaline common stock, after which Tourmaline will become a wholly owned subsidiary. Novartis said the acquisition adds a late-stage pipeline asset that complements its existing cardiovascular therapies. The deal is expected to close in the fourth quarter of 2025. Investors will be watching for updates on the integration and timi
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio (NASDAQ:TRML) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- $HAREHOLDER ALERT: The M&A Class Action Continues to Investigate Merger – TRML, PNFP, MRCC, and UNPGlobeNewswire
- Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLBusiness Wire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AL, TRML, SOL on Behalf of ShareholdersPR Newswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)PR Newswire
TRML
Earnings
- 8/13/25 - Beat
TRML
Sec Filings
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- TRML's page on the SEC website